Opinion
Video
Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative predictive value was lower at approximately 70%.
The ZIRCON Trial and Molecular Imaging
Main Discussion Topics:
Key Points for Physicians:
Notable Insights:
The high positive predictive value makes this a potentially valuable test when positive, though negative tests require careful interpretation.
Clinical Significance:
This molecular imaging approach represents a significant advance in noninvasive characterization of renal masses and may reduce unnecessary interventions.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.